A Study of ARRY-520 in Patients With Advanced Cancer

Exclusion Criteria

• •Treatment with an investigational product or device, or anti-neoplastic therapy (with the exclusion of hormone therapy where the therapy will continue at a standard dose throughout the study) within 28 days prior to the first dose of study drug.
• •Major surgery within 28 days prior to the first dose of study drug.
• •Radiotherapy (RT) within 28 days prior to the first dose of study drug (except if local RT to \<5% of the bone marrow).
• •Known positive serology for the human immunodeficiency virus (HIV), hepatitis C, and/or active hepatitis B.
• •Additional criteria exist.